Media

Summer Skin Crisis in Dogs & Cats: Scientific Solutions for Allergic Dermatitis & Pruritus with JAK MULTI Oclacitinib Tablets

Jun. 12, 2026

As summer brings high humidity and rising temperatures, veterinary clinics worldwide report a sharp increase in canine and feline skin disorders. Hot, damp conditions create the perfect environment for fungal infections, while seasonal pollen, dust mites and environmental irritants trigger widespread allergic reactions. Symptoms like persistent itching, redness, rashes, hair loss and secondary infections have become common complaints among pet owners. For dogs suffering from allergic dermatitis and atopic dermatitis, uncontrolled pruritus can lead to self-trauma, bacterial overgrowth and long-term skin damage. Against this backdrop, JAK MULTI (Oclacitinib Maleate Tablets) emerges as a science-backed solution to address the root cause of inflammatory skin conditions, providing fast-acting relief for summer skin flare-ups.

 

The Hidden Dangers of Summer Skin Issues

 

Many pet owners underestimate the severity of summer skin problems, treating itching as a minor nuisance rather than a symptom of underlying inflammation. In dogs, allergic dermatitis and atopic dermatitis are the most common culprits, with pruritus (itchiness) as the primary clinical sign. Left untreated, constant scratching leads to:

 

  • Self-inflicted wounds and hot spots

 

  • Secondary bacterial or fungal infections

​​​​​​​

  • Hair loss and permanent skin thickening

​​​​​​​

  • Reduced quality of life due to discomfort and sleep disruption

 

Traditional treatments like corticosteroids or antihistamines often come with significant side effects or delayed onset of action, leaving pets suffering while owners struggle to find a balance between efficacy and safety. Modern veterinary science has turned to targeted therapies that address the inflammatory cascade directly, without the systemic risks of long-term steroid use.

 

How JAK MULTI Delivers Targeted Relief
 

JAK MULTI contains Oclacitinib Maleate, a synthetic Janus kinase (JAK) inhibitor specifically designed to target the cytokines responsible for allergic and inflammatory pruritus in dogs. Unlike broad-spectrum anti-inflammatories, it works by selectively inhibiting JAK1 and JAK3 enzymes, which are critical to the signaling of pro-inflammatory and pruritogenic cytokines involved in allergic reactions. This targeted approach delivers three key benefits:

 

Fast-Acting Itch Relief Clinical studies show that JAK MULTI begins reducing pruritus within 24 hours, providing rapid comfort for dogs suffering from severe summer flare-ups. Unlike steroids, it does not require a “loading period” to take effect.

 

Reduced Risk of Side Effects By sparing JAK2-dependent cytokines involved in hematopoiesis, the formula minimizes interference with the immune system and blood cell production. This makes it suitable for long-term maintenance therapy when used as directed, with a more favorable safety profile compared to systemic corticosteroids.

 

Clear, Weight-Based Dosing Available in three strengths (3.6mg, 5.4mg, 16mg), the tablets are dosed at 0.4–0.6mg per kg of body weight, twice daily for 14 consecutive days, then once daily for maintenance. A detailed weight-based dosing table ensures accurate administration for dogs from 3kg to over 80kg.

 

The tablets are light brown, liver-flavored chewables, making administration easy even for picky eaters. They can be given with or without food, offering flexibility for pet owners.

 

Usage Guidelines & Safety Precautions

 

To ensure safe and effective use, JAK MULTI is indicated for use in dogs aged 12 months or older with a body weight of at least 3kg. It is not recommended for use in breeding, pregnant or lactating dogs, or those with severe infections, due to potential immune system modulation.

 

Pet owners should monitor dogs for signs of infection during treatment, including demodicosis, as JAK inhibitors may increase susceptibility to pathogens. In case of accidental ingestion by humans, immediate medical attention is required, with the full product details provided to healthcare providers.

 

Manufactured under strict quality standards, JAK MULTI has a shelf life of 24 months when stored at 20–25°C, with temporary transport at 15–40°C permitted. The product is packaged as 1.2g tablets in boxes of 10, making it convenient for both clinical and home use.

 

Summer skin flare-ups don’t have to mean months of discomfort for dogs. JAK MULTI offers a targeted, science-backed solution that addresses the root cause of allergic and atopic pruritus, delivering fast relief without the downsides of traditional therapies. By combining clear dosing guidelines with a favorable safety profile, it provides pet owners and veterinarians with a reliable tool to help dogs enjoy a comfortable, itch-free summer.

新闻图片生成指令.png

Imidacloprid and Moxidectin Spot-on Solutions for Dogs
Imidacloprid and Moxidectin Spot-on Solutions for Dogs
Introducing Imidacloprid and Moxidectin Spot-on Solutions for Dogs—your ultimate defense against internal and external parasites. This powerful duo not only prevents but also treats pesky infestations, ensuring your furry friend stays healthy and happy. Trust in this effective solution to safeguard your dog from unwanted invaders with every application.
JAK MULTI Oclacitinib Maleate Tablets for Dogs
JAK MULTI Oclacitinib Maleate Tablets for Dogs
Introducing Oclacitinib Maleate Tablets—specifically formulated to provide relief from pruritus due to allergic dermatitis and atopic dermatitis in dogs. These effective tablets help restore your furry friend's comfort and quality of life, ensuring they can enjoy their days free from the discomfort of itching. Celebrate their happiness with Oclacitinib!
JAK PLUS Compound Oclacitinib Maleate Chewable Tablets
JAK PLUS Compound Oclacitinib Maleate Chewable Tablets
Introducing Compound Oclacitinib Maleate Chewable Tablets, the effective solution for controlling pruritus caused by allergic dermatitis and managing atopic dermatitis in dogs. With its easy-to-administer chewable format, these tablets provide rapid relief, ensuring your furry friend feels comfortable and happy. Give your dog the relief they deserve!
Viclaner chewable tablets for dog
Viclaner chewable tablets for dog
Character : Light brown to dark brown round piece Main ingredient: Fluralaner 112.5mg 250mg 500mg 1000mg 1400mg Indication: It is used to treat flea and tick infection on the dog's body surface, and can also assist in the treatment of allergic dermatitis caused by fleas.
Terbinafine Hydrochloride Spray
Terbinafine Hydrochloride Spray
Terbinafine hydrochloride is a broad-spectrum antifungal drug of the allylamine class.
Terbinafine Hydrochloride Tablets
Terbinafine Hydrochloride Tablets
Terbinafine hydrochloride is an allylamine-class drug with broad-spectrum antifungal activity.
Imidacloprid and Moxidectin Spot-on Solutions for Cats
Imidacloprid and Moxidectin Spot-on Solutions for Cats
Introducing our Imidacloprid and Moxidectin Spot-on Solution for Cats—your go-to solution for comprehensive parasitic protection! This powerful formula prevents and treats flea infections, ear mites, and gastrointestinal nematodes, while also preventing heartworm and aiding in the relief of flea-induced allergic dermatitis. Keep your feline friend healthy and happy!
GET IN TOUCH
Needs Help? Let’s Get in Touch
    • aaa--bbbb
    • Afghanistan
    • Albania
    • Algeria
    • American Samoa
    • Andorra
    • Angola
    • Anguilla
    • Antarctica
    • Antigua and Barbuda
    • Argentina
    • Armenia
    • Aruba
    • Australia
    • Austria
    • Azerbaijan
    • Bahamas
    • Bahrain
    • Bangladesh
    • Barbados
    • Belarus
    • Belgium
    • Belize
    • Benin
    • Bermuda
    • BBhutan
    • Bolivia
    • Bosnia and Herzegovina
    • Botswana
    • Bouvet Island
    • Brazil
    • British Indian Ocean Territory
    • Brunei Darussalam
    • Bulgaria
    • Burkina Faso
    • Burundi
    • Cambodia
    • Cameroon
    • Canada
    • Cape Verde
    • Cayman Islands
    • Central African Republic
    • Chad
    • Chile
    • China
    • Christmas Island
    • Cocos (Keeling) Islands
    • Colombia
    • Comoros
    • Congo
    • Cook Islands
    • Costa Rica
    • Cote D'Ivoire
    • Croatia
    • Cuba
    • Cyprus
    • Czech Republic
    • Denmark
    • Djibouti
    • Dominica
    • East Timor
    • Ecuador
    • Egypt
    • El Salvador
    • Equatorial Guinea
    • Eritrea
    • Estonia
    • Ethiopia
    • Falkland Islands (Malvinas)
    • Faroe Islands
    • Fiji
    • Finland
    • France, Metropolitan
    • French Guiana
    • French Polynesia
    • Gabon
    • Gambia
    • Georgia
    • Germany
    • Ghana
    • Gibraltar
    • Greece
    • Greenland
    • Grenada
    • Guadeloupe
    • Guam
    • Guatemala
    • Guinea
    • Guinea-Bissau
    • Guyana
    • Haiti
    • Honduras
    • Hong Kong, China
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Iran (Islamic Republic of)
    • Iraq
    • Ireland
    • Israel
    • Italy
    • Jamaica
    • Japan
    • Jordan
    • Kazakhstan
    • Kenya
    • Kiribati
    • North Korea
    • South Korea
    • Kuwait
    • Kyrgyzstan
    • Lao People's Democratic Republic
    • Latvia
    • Lebanon
    • Lesotho
    • Liberia
    • Libyan Arab Jamahiriya
    • Liechtenstein
    • Lithuania
    • Luxembourg
    • Macau
    • Madagascar
    • Malawi
    • Malaysia
    • Maldives
    • Mali
    • Malta
    • Marshall Islands
    • Martinique
    • Mauritania
    • Mauritius
    • Mayotte
    • Mexico
    • Micronesia
    • Moldova
    • Monaco
    • Mongolia
    • Montserrat
    • Morocco
    • Mozambique
    • Myanmar
    • Namibia
    • Nauru
    • Nepal
    • Netherlands
    • New Caledonia
    • New Zealand
    • Nicaragua
    • Niger
    • Nigeria
    • Niue
    • Norfolk Island
    • Northern Mariana Islands
    • Norway
    • Oman
    • Pakistan
    • Palau
    • Panama
    • Papua New Guinea
    • Paraguay
    • Peru
    • Philippines
    • Pitcairn
    • Poland
    • Portugal
    • Puerto Rico
    • Qatar
    • Reunion
    • Romania
    • Russian Federation
    • Rwanda
    • Saint Kitts and Nevis
    • Saint Lucia
    • Saint Vincent and the Grenadines
    • Samoa
    • San Marino
    • Saudi Arabia
    • Senegal
    • Seychelles
    • Sierra Leone
    • Singapore
    • Slovak Republic
    • Slovenia
    • Solomon Islands
    • Somalia
    • South Africa
    • Spain
    • Sri Lanka
    • St. Helena
    • Sudan
    • Suriname
    • Swaziland
    • Sweden
    • Switzerland
    • Syrian Arab Republic
    • Taiwan, China
    • Tajikistan
    • Tanzania
    • Thailand
    • Togo
    • Tokelau
    • Tonga
    • Trinidad and Tobago
    • Tunisia
    • Turkey
    • Turkmenistan
    • Turks and Caicos Islands
    • Tuvalu
    • Uganda
    • Ukraine
    • United Arab Emirates
    • United Kingdom
    • United States
    • Uruguay
    • Uzbekistan
    • Vanuatu
    • Vatican City State (Holy See)
    • Venezuela
    • Viet Nam
    • Virgin Islands (U.S.)
    • Wallis and Futuna Islands
    • Western Sahara
    • Yemen
    • Zambia
    • Zimbabwe
    • Montenegro
    • Serbia
    • Palestine
    • South Sudan
    • Jersey